Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 27 Fallopian Tube Neoplasms 9 Prostatic Neoplasms 8 Breast Neoplasms 8 Neoplasms 6 Pancreatic Neoplasms 5 Endometrial Neoplasms 5 Neoplasm Metastasis 4 Triple Negative Breast Neoplasms 3 Mesothelioma 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Glioblastoma 3 Carcinoma, Ovarian Epithelial 3 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Recurrence 2 Mesothelioma, Malignant 2 Melanoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Uveal Melanoma 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urogenital Neoplasms 1 Thrombocytopenia 1 Stomach Neoplasms 1

Interventions

Cisplatin 66 Paclitaxel 32 Radiotherapy 31 Carboplatin 23 Bevacizumab 21 pembrolizumab 20 Brachytherapy 18 atezolizumab 11 Nivolumab 10 Gemcitabine 10 camrelizumab 9 tislelizumab 8 Topotecan 8 Taxes 8 Drug Therapy 8 Radiation 7 Docetaxel 7 Chemoradiotherapy 7 zimberelimab 6 toripalimab 6 nimotuzumab 6 Magnetic Resonance Spectroscopy 6 Cetuximab 6 Albumin-Bound Paclitaxel 6 lenvatinib 5 durvalumab 5 dostarlimab 5 Platinum 5 Papillomavirus Vaccines 5 Injections 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Uterine Cervical Neoplasms × niraparib × Clear all

NCT04068753 2026-02-10

STAR

University of Oklahoma

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡